TXG
10x Genomics, Inc.
Set alert
70.11 USD -11.44 -14.03%
67.42 Day range 75.77
12.44 52-week range 97.74
- YTD
- +329.86%
- 1 year
- +463.59%
- Open
- 73.65
- Prev close
- 81.55
- Mkt cap
- 9.13B
- Vol
- 5.22M
- Avg vol
- 3.37M
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 67.42
- High
- 75.77
- Forward P/E
- 913.53
- Beta
- 1.99
- Short ratio
- 3.09
- Inst. own
- 116.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.05
- 200-d avg
- 40.33
- 1y target
- 77.50
Financial health
Altman Z-Score
26.23 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 1
Valuation
P/E -46.6×
FY 2017 5y median -25.7× FY 2025
P/S 3.2×
FY 2017 5y median 8.0× FY 2025
P/B 2.6×
FY 2017 5y median 5.1× FY 2025
P/FCF 15.6×
FY 2017 5y median -101× FY 2025
EV/EBITDA 440×
FY 2017 5y median -30.7× FY 2025
EV/Sales 2.7×
FY 2017 5y median 7.8× FY 2025
FCF Yield 6.4%
FY 2017 5y median -0.7% FY 2025
Profitability
Gross Margin 69.1%
FY 2017 5y median 69.1% FY 2025
Operating Margin -17.2%
FY 2017 5y median -31.9% FY 2025
Net Margin -6.8%
FY 2017 5y median -29.9% FY 2025
ROE -5.5%
FY 2017 5y median -20.6% FY 2025
ROIC -12.3%
FY 2017 5y median -18.5% FY 2025
ROA -4.2%
FY 2017 5y median -16.1% FY 2025
Growth (YoY)
Revenue 5.2%
FY 2017 FY 2025
Operating Income 43.0%
FY 2017 FY 2025
EPS (diluted) 77.0%
FY 2017 FY 2025
Free Cash Flow 2371.2%
FY 2017 FY 2025
Financial Health
Current Ratio 4.5×
FY 2017 5y median 4.8× FY 2025
Quick Ratio 4.1×
FY 2017 5y median 4.2× FY 2025
Debt / Equity 0.2×
FY 2017 5y median 0.1× FY 2025
Net Debt / EBITDA -80.9×
FY 2017 5y median 1.3× FY 2025
Interest Coverage 0.0×
FY 2017 5y median -353× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31